OTCMKTS:DMTTF Small Pharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Small Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.08 -0.01 (-11.52%) (As of 07/5/2022 12:00 AM ET) Add Compare Share Today's Range$0.08▼$0.0950-Day Range$0.08▼$0.1652-Week Range$0.06▼$0.97Volume9,877 shsAverage Volume50,893 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$2.50 ProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest Small Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3,155.6% Upside$2.50 Price TargetShort InterestBearishDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.27 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSmall Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, Small Pharma has a forecasted upside of 3,155.6% from its current price of $0.08.Amount of Analyst CoverageSmall Pharma has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverSmall Pharma has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Small Pharma has recently increased by 29.05%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSmall Pharma does not currently pay a dividend.Dividend GrowthSmall Pharma does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DMTTF. Previous Next 1.1 News and Social Media Coverage News SentimentSmall Pharma has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 1 news article for Small Pharma this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Small Pharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DMTTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Small Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About Small PharmaSmall Pharma Inc., a biotechnology company, develops short-acting psychedelics for the treatment of mental health conditions. The company's lead product candidate is SPL026, a treatment for depressive disorder that is in Phase IIa trial. Its preclinical product candidates include SPL028 and SPL029 tryptamine analogues; and SPL801, an oral formulation of 6 -hydroxynorketamine. The company is headquartered in London, United Kingdom.Read More DMTTF Stock News HeadlinesJuly 3, 2022 | americanbankingnews.comSmall Pharma Inc. (OTCMKTS:DMTTF) Short Interest UpdateJune 23, 2022 | benzinga.comDMT Therapy Developer Small Pharma Posts Financial Results, Reaffirms Potential Of Short-Acting PsychedelicsJune 22, 2022 | finance.yahoo.comSmall Pharma to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022June 13, 2022 | ca.proactiveinvestors.comCanaccord Genuity repeats 'Speculative Buy' rating and $1.00 price target on Small Pharma following publication of its full-year resultsMay 30, 2022 | finance.yahoo.comSmall Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022May 25, 2022 | finance.yahoo.comSmall Pharma Shares Business Update Ahead of Annual Financial ResultsMay 9, 2022 | benzinga.comTRxADE HEALTH Reports First Quarter Revenue Growth of 6% and Q1 2022 Financial ResultsMay 6, 2022 | benzinga.comMaaT Pharma Reports Cash and Revenues for First Quarter 2022April 13, 2022 | msn.comPsychedelic Stock Gainers And Losers From April 13, 2022March 29, 2022 | msn.comPsychedelic Stock Gainers And Losers From March 29, 2022March 24, 2022 | msn.comAllied, Field Trip Health Among Top Psychedelic Movers Of TodayMarch 22, 2022 | msn.comMindset Pharma, Compass Pathways Among Top Psychedelic Movers Of TodayMarch 21, 2022 | msn.comField Trip Health, Mindset Pharma Among Top Psychedelic Movers Of TodayMarch 14, 2022 | msn.comWellbeing Digital, Small Pharma Among Top Psychedelic Movers Of TodayMarch 10, 2022 | finance.yahoo.comSmall Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic AssetsMarch 9, 2022 | finance.yahoo.comSmall Pharma to Participate in the 34th Annual Roth ConferenceFebruary 28, 2022 | msn.comPsychedelic Stock Gainers And Losers From February 28, 2022February 22, 2022 | msn.comPsychedelic Stock Gainers And Losers From February 22, 2022February 22, 2022 | finance.yahoo.comWorld’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase IFebruary 15, 2022 | msn.comPsychedelic Stock Gainers And Losers From February 15, 2022January 31, 2022 | finance.yahoo.comSmall Pharma Reports Fiscal Third Quarter 2021 HighlightsJanuary 21, 2022 | msn.comPsychedelic Stock Gainers And Losers From January 21, 2022January 4, 2022 | finance.yahoo.comSmall Pharma to Attend Upcoming Healthcare Conferences in January 2022December 1, 2021 | finance.yahoo.comSmall Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021November 15, 2021 | finance.yahoo.comDiscussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive DisorderSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Financial Conglomerates Sub-IndustryN/A SectorFinance Current SymbolOTCMKTS:DMTTF CUSIPN/A CIKN/A Webwww.smallpharma.co.uk Phone44 2071 129118FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.50 High Stock Price Forecast$2.50 Low Stock Price Forecast$2.50 Forecasted Upside/Downside+3,155.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Small Pharma Frequently Asked Questions Should I buy or sell Small Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Small Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Small Pharma stock. View analyst ratings for Small Pharma or view top-rated stocks. What is Small Pharma's stock price forecast for 2022? 1 Wall Street research analysts have issued twelve-month target prices for Small Pharma's shares. Their DMTTF stock forecasts range from $2.50 to $2.50. On average, they expect Small Pharma's stock price to reach $2.50 in the next year. This suggests a possible upside of 3,155.6% from the stock's current price. View analysts' price targets for Small Pharma or view top-rated stocks among Wall Street analysts. How has Small Pharma's stock price performed in 2022? Small Pharma's stock was trading at $0.25 on January 1st, 2022. Since then, DMTTF shares have decreased by 69.3% and is now trading at $0.0768. View the best growth stocks for 2022 here. Are investors shorting Small Pharma? Small Pharma saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 50,200 shares, an increase of 29.0% from the May 31st total of 38,900 shares. Based on an average daily trading volume, of 48,900 shares, the short-interest ratio is presently 1.0 days. View Small Pharma's Short Interest. Who are Small Pharma's key executives? Small Pharma's management team includes the following people: Mr. Peter David Rands, CEO & FounderMr. David Steel, Chief Financial OfficerDr. Carol Routledge, Chief Scientific & Medical OfficerMr. George Tziras, Chief Bus. OfficerMs. Marie Claire Layzell, Chief Manufacturing & Devel. OfficerDr. Alastair James Riddell M.D., M.Sc., MBChB, MFPM, MRCGP, MSc, Ph.D., Chief Operating Officer (Age 73)Mr. Richard M. Kimel HBA, LLB, Corp. Sec. (Age 55)Mr. Jim Rennie, Director of Devel. and Member of Scientific & Advisory Board Who are some of Small Pharma's key competitors? Some companies that are related to Small Pharma include 53511 (ISG.L) (ISG), Aetherium Acquisition (GMFIU), Alpha Healthcare Acquisition Corp. III (ALPAU), AltEnergy Acquisition (AEAEU), Altus Strategies (ALTUF), Andretti Acquisition (WNNRU), Anima (ANNMF), Apollo Strategic Growth Capital (APSGU), Atlantic Coastal Acquisition Corp. II (ACABU), Aurora Technology Acquisition (ATAKU), Avalon Acquisition (AVACU), B. Riley Financial (RILYP), Battery Future Acquisition (BFACU), Black Creek Industrial REIT IV (ZBCIIX) and Black Creek Industrial REIT IV (ZBCITX). View all of DMTTF's competitors. What is Small Pharma's stock symbol? Small Pharma trades on the OTCMKTS under the ticker symbol "DMTTF." How do I buy shares of Small Pharma? Shares of DMTTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Small Pharma's stock price today? One share of DMTTF stock can currently be purchased for approximately $0.08. How many employees does Small Pharma have? Small Pharma employs 13 workers across the globe. How can I contact Small Pharma? The official website for Small Pharma is www.smallpharma.co.uk. The company can be reached via phone at 44 2071 129118. This page (OTCMKTS:DMTTF) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
